Table 3 Management during the ICU stay and outcomes of 121 patients with ARF associated with Svv
All patients n = 121 | Immune ARF n = 67 | Non-immune ARF n = 54 | p | ||||
|---|---|---|---|---|---|---|---|
Immunosuppressive therapy, n (%) | 77 | (64) | 65 | (97) | 12 | (22) | < 0.0001 |
Systemic steroids | 75 | (62) | 65 | (97) | 10 | (19) | < 0.0001 |
High-dose pulses | 65 | (54) | 60 | (90) | 5 | (9) | < 0.0001 |
Cyclophosphamide | 45 | (37) | 42 | (63) | 3 | (6) | < 0.0001 |
Rituximab | 14 | (12) | 13 | (19) | 1 | (2) | 0.003 |
Plasma exchange | 37 | (31) | 34 | (51) | 3 | (6) | < 0.0001 |
Other treatments during the first 48 h, n (%) | |||||||
Blood transfusion | 51 | (42) | 40 | (60) | 11 | (20) | < 0.0001 |
Antibiotics | 106 | (88) | 60 | (90) | 46 | (85) | 0.47 |
Diuretics | 42 | (35) | 22 | (33) | 20 | (37) | 0.63 |
Management and outcomes in the ICU | |||||||
Invasive mechanical ventilation, n (%) | 60 | (50) | 34 | (49) | 26 | (50) | 0.94 |
ARDS, n (%) | 62 | (51) | 40 | (60) | 22 | (41) | 0.038 |
Ventilator-associated pneumonia, n (%) | 24 | (20) | 19 | (28) | 5 | (9) | 0.009 |
Ventilator-free days at day 28, days | 23 | [5–28] | 20 | [5–28] | 24 | [7–28] | 0.40 |
Shock (vasopressor treatment > 48 h) | 37 | (31) | 21 | (31) | 16 | (30) | 0.84 |
Renal replacement therapy | 57 | (47) | 35 | (52) | 22 | (41) | 0.21 |
Length of ICU stay (all patients) | 8 | [4–38] | 11 | [5–20] | 5.5 | [3–12] | 0.014 |
Length of ICU stay of survivors only | 10.5 | [5–23] | 13 | [7–25] | 7 | [4–17] | 0.018 |
Mortality, n (%) | |||||||
ICU | 23 | (19) | 10 | (15) | 13 | (24) | 0.20 |
Hospital | 29 | (24) | 11 | (16) | 18 | (33) | 0.030 |
Day 90a | 27/118 | (23) | 10/65 | (15) | 17/53 | (32) | 0.032 |
1 yeara | 33/118 | (28) | 13/65 | (20) | 20/53 | (38) | 0.033 |